Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-10-020364)

Filing Details

Accession Number:: 0001209191-10-020364
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-04-02 13:00:00
Reporting Period:: 2010-03-31

Filing Date:: 2010-04-02
Accepted Time:: 2010-04-02 18:57:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1012140	Onyx Pharmaceuticals Inc	ONXX	Biological Products, (No Disgnostic Substances) (2836)	943154463

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1282660	R Julianna Wood	C/O Onyx Pharmaceuticals, Inc. 2100 Powell St., 12Th Floor Emeryville CA 94608	Vp, Corp. Communication/I.r.	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-03-31	3,500	$0.00	12,249	No	4	A	Direct
Common Stock	Disposition	2010-03-31	618	$30.15	11,631	No	4	S	Direct
Common Stock	Disposition	2010-04-01	1,078	$30.10	10,553	No	4	S	Direct
Common Stock	Disposition	2010-04-01	2	$30.30	10,551	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2010-03-31	24,500	$0.00	24,500	$30.28

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
24,500		2020-03-31	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	200	Indirect	Children's Trust

Footnotes

Shares sold pursuant to a 10b5-1 plan.
12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.